Abstract MO42 – Table 1. Patient characteristics.
Baseline	Total N = 134	Dovato® N = 89	Biktarvy® N = 45
Dropouts after randomisation	13/134	9/89	5/45
Sex (M/F)	118/12	79/8	39/4
Age (year), median (IQR)	46 (37 to 54) n = 128	46 (36 to 53) n = 86	45 (40 to 56) n = 42
CD4 at screening (cells/μL), median (IQR)	689 (550.5 to 929.5) n = 125	691 (558 to 933) n = 83	676.5 (526.75 to 871.75) n = 42
CD4 nadir (cells/μL), median (IQR)	289 (168 to 424) n = 123	296.5 (165.75 to 449) n = 84	273 (194 to 385) n = 39
Peak viral load (copies/mL plasma), median (IQR)	97 646.5 (26 736.73 to 323 510.5) n = 114	122 563 (32 291.7 to 405 526.8) n = 76	62 447.85 (12 097.4 to 192 502.3) n = 38
Time on ART (year), median (IQR)	7.2 (4.6 to 10.8) n = 123	8.1 (4.75 to 11.15) n = 82	6 (4.35 to 8.95) n = 41
Time from start ART to undetectable viral load (year), median (IQR)	0.3 (0.2 to 0.4) n = 117	0.3 (0.2 to 0.4) n = 78	0.3 (0.1 to 0.7) n = 39
Total HIV‐1 DNA copies/10^6 CD4+ T cells, median (IQR)	651.83 (267.47 to 1322.92) n = 112	772.75 (419.53 to 1387.88) n = 75	511.41 (282.84 to 1482.83) n = 37
Intact proviral HIV‐1 DNA copies/10^6 CD4+ T cells, median (IQR)	21.21 (1.9 to 58.48) n = 87a	21.21 (2.07 to 41.56) n = 61	26.01 (0 to 108.68) n = 26
Week 48
Total HIV‐1 DNA copies/10^6 CD4+ T cells, median (IQR)	439.37 (189.14 to 1185.35) n = 108	503.87 (233.49 to 1246.49) n = 73	324.57 (140.95 to 1123.68) n = 35
Intact proviral HIV‐1 DNA copies/10^6 CD4+ T cells, median (IQR)	12.03 (2.55 to 41.68) n = 87	8.7 (0 to 37.37) n = 61	28.06 (4.75 to 63.45) n = 26
Delta week 48‐baseline
Total HIV‐1 DNA copies/10^6 CD4+ T cells, median (IQR)	‐122.67 (‐330.98 to 57.03) n = 108	‐131.26 (‐397.41 to ‐93.83) n = 73	‐112.18 (‐219.06 to 42.78) n = 35
Intact proviral HIV‐1 DNA copies/10^6 CD4+ T cells, median (IQR)	‐5.05 (‐28.57 to 14.56) n = 87	‐6.47 (‐30.00 to 15.87) n = 61	‐4.65 (‐18.67 to 14.94) n = 26

^aDataset (n = 112) further refined: only participants with quantifiable results at baseline were included.